Inozyme Pharma, Inc. (NASDAQ:INZY) Short Interest Update

Inozyme Pharma, Inc. (NASDAQ:INZY) was the recipient of a large increase in short interest in the month of March. As of March 31st, there was short interest totalling 2,580,000 shares, an increase of 8.4% from the March 15th total of 2,380,000 shares. Approximately 6.3% of the shares of the company are short sold. Based on an average daily volume of 611,300 shares, the short-interest ratio is currently 4.2 days.

Insider Buying and Selling at Inozyme Pharma

In other Inozyme Pharma news, CEO Douglas A. Treco sold 7,523 shares of the stock in a transaction on Tuesday, April 2nd. The shares were sold at an average price of $6.94, for a total value of $52,209.62. Following the completion of the sale, the chief executive officer now directly owns 20,665 shares of the company’s stock, valued at approximately $143,415.10. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 11.88% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Vanguard Group Inc. boosted its stake in shares of Inozyme Pharma by 4.8% in the 4th quarter. Vanguard Group Inc. now owns 2,385,022 shares of the company’s stock valued at $10,160,000 after purchasing an additional 108,937 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in shares of Inozyme Pharma by 574.3% in the 4th quarter. Goldman Sachs Group Inc. now owns 363,372 shares of the company’s stock valued at $1,548,000 after purchasing an additional 309,484 shares during the last quarter. American International Group Inc. boosted its stake in shares of Inozyme Pharma by 40.5% in the 4th quarter. American International Group Inc. now owns 23,730 shares of the company’s stock valued at $101,000 after purchasing an additional 6,838 shares during the last quarter. Virtu Financial LLC boosted its stake in shares of Inozyme Pharma by 153.6% in the 4th quarter. Virtu Financial LLC now owns 26,678 shares of the company’s stock valued at $114,000 after purchasing an additional 16,160 shares during the last quarter. Finally, Eventide Asset Management LLC boosted its stake in shares of Inozyme Pharma by 1.8% in the 4th quarter. Eventide Asset Management LLC now owns 3,179,837 shares of the company’s stock valued at $13,546,000 after purchasing an additional 54,837 shares during the last quarter. Institutional investors own 88.30% of the company’s stock.

Inozyme Pharma Trading Down 8.4 %

Shares of Inozyme Pharma stock opened at $4.71 on Tuesday. The stock has a market capitalization of $290.94 million, a P/E ratio of -3.39 and a beta of 1.37. The company has a quick ratio of 13.36, a current ratio of 13.36 and a debt-to-equity ratio of 0.32. The company has a 50-day simple moving average of $6.04 and a 200 day simple moving average of $4.64. Inozyme Pharma has a 12-month low of $2.69 and a 12-month high of $7.80.

Inozyme Pharma (NASDAQ:INZY) last posted its quarterly earnings data on Tuesday, March 12th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.04). Research analysts expect that Inozyme Pharma will post -1.46 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

INZY has been the subject of a number of analyst reports. Bank of America reduced their price objective on shares of Inozyme Pharma from $16.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, April 9th. Wedbush reaffirmed an “outperform” rating and set a $15.00 price objective on shares of Inozyme Pharma in a report on Monday, April 8th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Inozyme Pharma in a report on Wednesday, March 13th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $23.00 price objective on shares of Inozyme Pharma in a report on Tuesday, April 9th.

About Inozyme Pharma

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.